AR088764A1 - Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas - Google Patents

Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas

Info

Publication number
AR088764A1
AR088764A1 ARP120103710A ARP120103710A AR088764A1 AR 088764 A1 AR088764 A1 AR 088764A1 AR P120103710 A ARP120103710 A AR P120103710A AR P120103710 A ARP120103710 A AR P120103710A AR 088764 A1 AR088764 A1 AR 088764A1
Authority
AR
Argentina
Prior art keywords
sensory
methods
motor
aminopiridins
impediment
Prior art date
Application number
ARP120103710A
Other languages
English (en)
Spanish (es)
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AR088764A1 publication Critical patent/AR088764A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP120103710A 2011-10-04 2012-10-04 Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas AR088764A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
AR088764A1 true AR088764A1 (es) 2014-07-02

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103710A AR088764A1 (es) 2011-10-04 2012-10-04 Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas

Country Status (22)

Country Link
US (2) US20130085167A1 (enExample)
EP (1) EP2766017B1 (enExample)
JP (1) JP6134722B2 (enExample)
KR (1) KR20140084120A (enExample)
CN (2) CN108451953A (enExample)
AR (1) AR088764A1 (enExample)
AU (2) AU2012318719B2 (enExample)
BR (1) BR112014008082A8 (enExample)
CA (1) CA2850635A1 (enExample)
CL (1) CL2014000799A1 (enExample)
CO (1) CO7061067A2 (enExample)
CR (1) CR20140153A (enExample)
EA (1) EA029558B1 (enExample)
HK (1) HK1201204A1 (enExample)
IL (1) IL231809B (enExample)
MX (1) MX354667B (enExample)
PH (1) PH12014500739B1 (enExample)
SG (2) SG10201600410SA (enExample)
TW (1) TWI592156B (enExample)
UA (1) UA114486C2 (enExample)
WO (1) WO2013052575A1 (enExample)
ZA (1) ZA201402432B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
WO1989009600A1 (en) 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
DE60034110T2 (de) * 1999-02-09 2007-12-06 The Uab Research Foundation, Birmingham Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
CA2403555A1 (en) * 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy

Also Published As

Publication number Publication date
CR20140153A (es) 2014-07-04
EA029558B1 (ru) 2018-04-30
TW201321000A (zh) 2013-06-01
CN104220072B (zh) 2018-04-17
NZ623255A (en) 2016-08-26
AU2018200114A1 (en) 2018-01-25
PH12014500739B1 (en) 2019-05-10
EA201490562A1 (ru) 2014-08-29
EP2766017B1 (en) 2020-07-01
TWI592156B (zh) 2017-07-21
JP6134722B2 (ja) 2017-05-24
ZA201402432B (en) 2020-08-26
CL2014000799A1 (es) 2014-11-03
HK1201204A1 (en) 2015-08-28
SG11201401248YA (en) 2014-05-29
CN104220072A (zh) 2014-12-17
WO2013052575A1 (en) 2013-04-11
MX354667B (es) 2018-03-15
BR112014008082A2 (pt) 2017-07-18
IL231809B (en) 2019-06-30
AU2012318719A1 (en) 2014-04-17
BR112014008082A8 (pt) 2018-01-16
CN108451953A (zh) 2018-08-28
US20130085167A1 (en) 2013-04-04
AU2012318719B2 (en) 2017-10-19
CA2850635A1 (en) 2013-04-11
UA114486C2 (uk) 2017-06-26
US20160067232A1 (en) 2016-03-10
HK1204965A1 (en) 2015-12-11
EP2766017A1 (en) 2014-08-20
CO7061067A2 (es) 2014-09-19
SG10201600410SA (en) 2016-02-26
JP2014531470A (ja) 2014-11-27
PH12014500739A1 (en) 2014-05-26
KR20140084120A (ko) 2014-07-04
MX2014003997A (es) 2014-07-22
IL231809A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
AR089993A1 (es) Macrociclos peptidomimeticos
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2015003140A (es) Formulaciones de enzalutamida.
MX353827B (es) Formas de rifaximina y usos de la misma.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CL2013002934A1 (es) Polimeros conjugados analogos de prostaglandinas; metodo de preparacion; implante y uso en el tratamiento del glaucoma.
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
BR112015012443A2 (pt) composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza
AR088764A1 (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas
AR078323A1 (es) Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple
HRP20180345T1 (hr) Derivati sterola i njihova upotreba u liječenju bolesti koje uključuju transformirane astrocitne stanice, ili u liječenju zloćudnih hemopatija
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
EA201590782A1 (ru) Оксирановые амины

Legal Events

Date Code Title Description
FB Suspension of granting procedure